“We are delighted to welcome Elisabeth as our chief commercial officer. She is a proven executive with extensive experience building and leading commercial teams and programs for physicians and consumers and she is also accomplished in launching into a new market segment with a novel drug product,” said Randall C. Schatzman, Ph.D., president and chief executive officer. “As we progress ALD403 toward an FDA submission and our goal of marketing a best-in-class migraine prevention antibody therapy, we look forward to leveraging Elisabeth’s creativity and expertise to advance our commercialization strategy, build a specialty sales force and successfully market ALD403, if approved, to the millions of migraine sufferers in the U.S. that are candidates for prevention therapy.”
Ms. Sandoval brings 30 years of experience in the pharmaceutical and medical device industry spanning research and development, sales management, marketing strategy, and commercial launch planning and execution. Most recently, she served as the chief commercial officer of Kythera Biopharmaceuticals, Inc. where she built a commercial team from the ground up for the successful U.S. launch of KYBELLA, a first in class drug product that created a new market segment. Prior to joining Kythera in 2012, Ms. Sandoval served as vice president of global marketing and strategy at Bausch + Lomb Surgical. From 1988 to 2010, she held roles of increasing responsibility at Allergan including global vice president, strategic marketing and senior director of global strategic marketing, which included responsibility for multiple products including Botox® for neurological and other disorders. She began her career in research and development at Ethicon, a subsidiary of Johnson & Johnson. Ms. Sandoval holds a bachelor’s degree in biology from the University of California, Irvine, and an MBA from Pepperdine University.
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, ALD403, is being evaluated for migraine prevention. ALD403 is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
This press release contains forward-looking statements, including, without limitation, statements relating to: the continued development and clinical, therapeutic and commercial potential of ALD403; future regulatory filings; and the anticipated commercialization of ALD403. Words such as “advancement,” “development,” “execution,” “strategy,” “progress,” “goal,” “look forward,” “build,” “market,” or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Alder’s current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: risks related to the potential failure of ALD403 to demonstrate safety and efficacy in clinical testing; Alder’s ability to conduct clinical trials of ALD403 sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of ALD403; risks and uncertainties related to regulatory application, review and approval processes and Alder’s compliance with applicable legal and regulatory requirements; the uncertain timing and level of expenses associated with the development of ALD403; the sufficiency of Alder’s capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption “Risk Factors” in Alder’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2016, which was filed with the Securities and Exchange Commission (SEC) on July 26, 2016, and is available on the SEC’s website atwww.sec.gov. Additional information will also be set forth in Alder’s other reports and filings it will make with the SEC from time to time. The forward-looking statements made in this press release speak only as of the date of this press release. Alder expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Alder’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.